Drug Profile


Alternative Names: Actilyse; Activacin; Activase; Cathflo; G-11021; G-11035; G-11044; GMK-527; GRTPA; Recombinant tissue plasminogen activator - Boehringer; RG-3626; rt-PA - Boehringer; rTPA - Boehringer; t-PA - Boehringer; Tissue plasminogen activator - Boehringer; Tissue type plasminogen activator - Boehringer

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Catheter thrombosis; Myocardial infarction; Pulmonary embolism; Stroke

Most Recent Events

  • 01 Nov 2016 Boehringer Ingelheim initiates enrolment in a phase III trial for Stroke in China (NCT02930837)
  • 10 Oct 2016 Boehringer Ingelheim plans a phase III trial for Stroke in China (NCT02930837)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top